President Trump is right to center his health policy agenda on making health care more affordable and advancing America’s interests abroad. But the policies he has pursued thus far have sometimes undercut the pursuit of those goals.
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure.
But the results of his efforts to date have been mixed.
Consider Trump’s approach to prescription drug prices. For years, Americans have been clamoring for policies that will make drugs more affordable.
But policymakers also must ensure they don’t kill the metaphorical golden goose that has delivered life-saving therapies to patients worldwide. Intervening too aggressively in the pharmaceutical market could destroy incentives for investors and drug companies to spend billions developing cutting-edge medicines — and undermine our economy and status as the world leader in biotechnology.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Trump Delivers Mixed Results on Health Reform
Sally C. Pipes
President Trump is right to center his health policy agenda on making health care more affordable and advancing America’s interests abroad. But the policies he has pursued thus far have sometimes undercut the pursuit of those goals.
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure.
But the results of his efforts to date have been mixed.
Consider Trump’s approach to prescription drug prices. For years, Americans have been clamoring for policies that will make drugs more affordable.
But policymakers also must ensure they don’t kill the metaphorical golden goose that has delivered life-saving therapies to patients worldwide. Intervening too aggressively in the pharmaceutical market could destroy incentives for investors and drug companies to spend billions developing cutting-edge medicines — and undermine our economy and status as the world leader in biotechnology.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.